NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- B-Cell Lymphoma
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00054665
- Locations
- 🇺🇸
Roswell Parck Cancer Institute, Buffalo, New York, United States
🇺🇸National Cancer Institute (NCI), Bethesda, Maryland, United States
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00054535
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Phase 1
Completed
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00054483
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
Phase 1
Terminated
- Conditions
- Disseminated NeuroblastomaRecurrent Neuroblastoma
- Interventions
- Biological: filgrastimProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantationOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00053950
- Locations
- 🇺🇸
New Approaches to Neuroblastoma Treatment (NANT), Los Angeles, California, United States
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
Phase 1
Terminated
- Conditions
- Recurrent Neuroblastoma
- Interventions
- Biological: recombinant interleukin-12Biological: aldesleukin
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00054405
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸New Approaches to Neuroblastoma Treatment (NANT), Los Angeles, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
Phase 1
Completed
- Conditions
- Recurrent Breast CancerStage IIIB Breast CancerStage IV Breast Cancer
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00054028
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Phase 2
Completed
- Conditions
- Stage IV Breast CancerRecurrent Breast Carcinoma
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT00054132
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸UCSF Medical Center-Mount Zion, San Francisco, California, United States
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Phase 2
Completed
- Conditions
- Recurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic LymphomaIntraocular LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Marginal Zone LymphomaTesticular LymphomaWaldenström Macroglobulinemia
- Interventions
- Biological: oblimersen sodiumBiological: rituximabOther: laboratory biomarker analysis
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00054639
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT00053365
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma
Phase 2
Completed
- Conditions
- Recurrent Neuroblastoma
- Interventions
- Other: pharmacological study
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00053326
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
© Copyright 2025. All Rights Reserved by MedPath